ArticleBMC infectious diseases2026
Mortality and its predictors among adolescents and adults on antiretroviral therapy in the era of test-and-treat, Ethiopia: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHIV/AIDS remains a leading cause of morbidity and mortality in resource-limited settings. Although several studies have assessed mortality among patients on antiretroviral therapy (ART), evidence from Ethiopia during the test-and-treat era, where all diagnosed individuals start ART immediately regardless of clinical stage or CD4 count, is limited.
methodsA retrospective cohort study was conducted at public hospitals in the West Arsi Zone, involving 446 adolescents and adults on ART between August 2016 and June 2019. Participants were selected by stratified random sampling at three randomly selected hospitals. Data were extracted from the patient cards and electronic databases. Cox proportional hazard regression was fitted to identify predictors of mortality.
resultsAmong 446 patients followed for 13,860 person-months, early mortality predominated, with 28 (59.57%) deaths occurring within the first 6 months of ART initiation. Overall, 47 (10.54%) patients died, yielding an all-cause mortality rate of 4.07 (95% CI: 3.14–5.19) per 100 person-years. The cumulative survival at the end of follow-up was 87.37% (95% CI: 83.46–90.41). The predictors of mortality were age group > 35 (AHR 2.51, 95% CI: 1.17–5.37), rural residence (AHR 1.77, 95% CI: 1.09–2.89), WHO clinical stage 3 or 4 (AHR 4.16, 95% CI: 1.89–9.16), bedridden functional status (AHR 8.48, 95% CI: 3.19–22.52), TB coinfection (AHR 3.69, 95% CI: 1.95–6.98), moderate or severe anemia (AHR 4.15, 95% CI: 2.16–7.97), and non-disclosure of HIV status (AHR 3.86, 95% CI: 1.93–7.72).
conclusionThis study highlights substantial early mortality among patients receiving ART and identified key clinical and demographic predictors of mortality. These findings underscore the need for targeted interventions to improve survival outcomes. Policy makers and program managers should prioritize early diagnosis and treatment initiation, strengthen tuberculosis screening programs and disclosure counseling, and ensure close monitoring of patients with advanced disease, anemia, and those residing in rural areas.
trial registrationClinical trial number: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.